Mounjaro vs Ozempic for Weight Loss | Key Differences
Mounjaro vs Ozempic for Weight Loss: Key Differences
Mounjaro (tirzepatide) → Dual action (GLP-1 + GIP)
Ozempic (semaglutide) → GLP-1 receptor agonist
What Is the Difference?
Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors. Ozempic contains semaglutide, which activates the GLP-1 receptor. Both can improve glucose regulation and reduce appetite, but they are different medicines with different approved indications and dosing schedules.
Weight Loss Evidence
In the SURMOUNT-5 head-to-head trial in adults with overweight or obesity without Type 2 Diabetes, tirzepatide produced greater average weight reduction than semaglutide over 72 weeks. Mean weight change was approximately 20.2% with tirzepatide versus 13.7% with semaglutide. Individual response varies, and trial results should not be treated as a guarantee for any patient.
Diabetes and HbA1c
In SURPASS-2, a trial in people with Type 2 Diabetes receiving metformin, tirzepatide produced greater average HbA1c and body-weight reductions than semaglutide 1 mg at 40 weeks. Treatment choice still depends on the individual’s HbA1c target, other medicines, comorbidities, tolerability, access and cost.
Side Effects and Safety
Both medicines commonly cause gastrointestinal effects such as nausea, vomiting, diarrhea, constipation and abdominal discomfort, especially during dose escalation. Patients using insulin or insulin-secretagogue medicines may need medication adjustment because of hypoglycemia risk. Severe or persistent abdominal pain, repeated vomiting or significant dehydration warrants medical assessment.
How to Choose Between Them
- Type 2 Diabetes versus chronic Weight Management indication
- Current HbA1c, weight and metabolic risk
- Other medicines, especially insulin and sulfonylureas
- Previous response or intolerance to GLP-1-based treatment
- Cardiovascular, kidney and gastrointestinal considerations
- Product availability, approved indication and affordability
- Patient preference and ability to follow the prescribed plan
📊 Head-to-head comparison
1. Blood sugar (HbA1c)
- Tirzepatide produced greater average HbA1c reduction than semaglutide 1 mg in SURPASS-2.
- Example: ~–1.3% vs –0.9% in real-world data
- Clinical trials also show slightly greater reduction with tirzepatide
Evidence summary: Tirzepatide produced greater average HbA1c reduction than semaglutide 1 mg in SURPASS-2, but individual treatment selection remains clinical and patient-specific.
2. Weight loss
- Head-to-head Weight Management evidence found greater average weight reduction with tirzepatide in the studied population.
- Example:
- ~10.2 kg vs 6.1 kg
- Up to 47% greater weight loss in trials
Evidence summary: Head-to-head Weight Management evidence has shown greater average weight reduction with tirzepatide than semaglutide in the studied population.
3. Mechanism advantage
- Mounjaro → Works on two hormones (GLP-1 + GIP) → stronger appetite suppression & insulin response
- Ozempic → Only GLP-1
Mechanistic difference: Tirzepatide targets GIP and GLP-1 receptors, while semaglutide targets GLP-1 receptors.
4. Side effects
- Very similar:
- Nausea
- Vomiting
- Diarrhea
- No major safety difference overall
Safety: Both have important gastrointestinal adverse effects and require individualized medical monitoring.
5. Cost & availability (India context)
- Ozempic → usually more available / cheaper
- Mounjaro → costlier, newer drug
Cost and access: Prices and availability vary by product, dose and pharmacy in India and should be checked at the time of treatment.
6. Cardiovascular evidence
- Semaglutide (Ozempic/Wegovy) has strong CV outcome data
- Tirzepatide data is emerging
Cardiovascular evidence: Semaglutide has established cardiovascular outcome evidence in relevant populations; cardiovascular history should be considered when choosing therapy.
Practical Summary
| Question | Evidence / consideration |
|---|---|
| Weight reduction | Head-to-head evidence found greater average weight reduction with tirzepatide in the studied population. |
| HbA1c reduction | SURPASS-2 found greater average HbA1c reduction with tirzepatide versus semaglutide 1 mg. |
| Cost and availability | Varies by product, dose, pharmacy and location in India. |
| Cardiovascular considerations | Semaglutide has established cardiovascular outcome evidence in relevant populations; individual cardiovascular risk should guide treatment selection. |
| First-time treatment | Choice depends on indication, medical history, tolerability, access, cost and clinician assessment. |
Clinical Takeaway
For more detail, read the Mounjaro (Tirzepatide) guide, Semaglutide for Weight Loss guide, Yurpeak (Tirzepatide) guide, or GLP-1 Specialist in Ahmedabad guide.
- Tirzepatide may produce greater average Weight Loss in head-to-head trial populations.
- Semaglutide remains an established GLP-1 option with substantial clinical evidence.
- Both require appropriate patient selection, dose escalation and medical follow-up.
